Acceleron veterans and Westlake back new IPF biotech Oorja Bio with $30 million Series A
Entrepreneurs who previously brought the drug Winrevair to market have launched a new biotech, Oorja Bio, to target idiopathic pulmonary fibrosis, a hard-to-treat lung disease.
The company announced a $30 million Series A financing round, with all capital coming from Westlake and participation from leaders of Acceleron. The investors are providing both cash and strategic guidance.
Oorja Bio plans to use the funding to advance its IPF program, aiming to develop novel therapies for patients with limited options. The strong backing highlights investor confidence in the unmet need and the team's track record.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Acceleron leaders and Westlake jumpstart new IPF biotech”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that